Corvidane
Developing a novel, safe drug to prevent heart attacks, strokes, and liver transplants from NASH
Overview
Raised: $371,284
Total Commitments ($USD)
Wefunder
01/03/2022
04/30/2022
$100
SAFE
Pre-Seed
RegCF
$19,000,000
$20,000,000
10%
Rolling Commitments ($USD)
04/30/2022
$3,201
229
2014
Healthcare & Pharmaceuticals
HealthTech
B2B/B2C
Medium
High
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$-33,665 |
$-39,724 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$2,738 |
$12,851 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$69,379 |
$67,875 |
|
Short-Term Debt |
$80,607 |
$64,755 |
|
Long-Term Debt |
$0 |
$0 |
|
Total Liabilities |
$80,607 |
$64,755 |
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.
Valuation History
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Employee History
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
